Sigma Planning Corp Arbutus Biopharma Corp Transaction History

Sigma Planning Corp

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Oct 28, 2021	SELL	$2.65 - $4.62 $39,750 - $69,300	-15,000 Reduced 57.69%	11,000 $47,000
Q2 2021 Aug 13, 2021	SELL	$2.5 - $3.51 $725 - $1,017	-290 Reduced 1.1%	26,000 $79,000
Q1 2021 May 06, 2021	BUY	$3.14 - $4.84 $82,550 - $127,243	26,290 New	26,290 $88,000

194

118M

2.67M

693K

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $678M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

Get notified when there are updates to the investment portfolio of Sigma Planning Corp, based on Form 13F filings with the SEC.

Stay updated on Sigma Planning Corp with notifications on news.